STEINMAN LAWRENCE

SEC Form 4 insider trading activity

STEINMAN LAWRENCE has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Dec 1, 2025.

On the most recent filing, STEINMAN LAWRENCE is listed as Director at Pasithea Therapeutics Corp. Inside the rolling window, STEINMAN LAWRENCE reported 1 open-market purchase totaling $100K in KTTA and no open-market sales.

Companies traded

Other insiders at KTTA

Insider Buying

$100K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
KTTA
STEINMAN LAWRENCE
Purchase$100KDec 1SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has STEINMAN LAWRENCE made?

STEINMAN LAWRENCE has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2025.

Which companies does STEINMAN LAWRENCE trade?

STEINMAN LAWRENCE has filed SEC Form 4 disclosures for 1 company, including KTTA.

When was STEINMAN LAWRENCE's most recent SEC Form 4 filing?

STEINMAN LAWRENCE's most recent SEC Form 4 filing on Tracefour is dated Dec 1, 2025.

What is STEINMAN LAWRENCE's total buy and sell value in the current window?

Inside the rolling retention window, STEINMAN LAWRENCE bought $100K and sold $0 based on SEC Form 4 filings.

What was STEINMAN LAWRENCE's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 133,333 KTTA shares on 2025-11-28, worth $100K, per SEC Form 4 filings.